Catalyst
Slingshot members are tracking this event:
Phase 2 interim data of GI-6207 for medullary thyroid cancer due Jan 2019 - Acquired by NantCell, Inc.
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GBIM | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 23, 2017
Occurred Source:
https://www.prnewswire.com/news-releases/globeimmune-announces-majority-stock-sale-300428679.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2 Data, Gi-6207, Medullary Thyroid Cancer, 2h 2016, Mtc
